

STEFAN J. KLAUBER  
DAVID A. JACKSON  
ALLAN H. FRIED\*  
MICHAEL D. DAVIS\*  
STEVE S. CHA  
LAWRENCE D. MANDEL\*  
STEVEN GIGANTE

\* BAR OTHER THAN N.J.  
\* COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.  
MICHAEL A. YAMIN, PH.D.

**KLAUBER & JACKSON**  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

February 16, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application  
Serial No. : 09/554,547  
Filed : July 7, 2000  
Inventors : Guido Christiaan PAESEN *et al*  
Title : TISSUE CEMENT  
Docket No. : 2488-1-001

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on February 16, 2001.

David A. Jackson, Reg. No. 26,742  
(Name of Registered Representative)

*David A. Jackson* 2/16/01  
(Signature and Date)

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

Responsive to the Notice dated January 19, 2001, and in accordance with 37 CFR 1.821 - 1.825, Applicants submit herewith the following:

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.

BOX 500  
GAU-1633  
#10/108  
9/27/01

PATENT, TRADEMARK AND  
COPYRIGHT CAUSES

(201) 487-5800

FACSIMILE: (201) 343-1684

WWW.KJILAW.COM

email: info@kjiplaw.com

**RECEIVED**

FEB 22 2001

TECH CENTER 1600/2900

U.S. PATENT & TRADEMARK OFFICE  
RECEIVED  
FEB 22 11:50 AM  
TECH CENTER 1600/2900

**RECEIVED**

FEB 26 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
February 16, 2001  
Page2


Attorney Docket No.: 2488-1-001

2. A copy of the Sequence Listing in computer readable form.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
4. Amendment directing entry of the Sequence Listing into the specification.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.


Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,

  
DAVID A. JACKSON  
Attorney for Applicant(s)  
Registration No. 26,742

DAJ:ls  
Enclosures

RECEIVED  
FEB 20 2001  
CIPD 22 PM 5:01



## Notice to Comply

Application No.

09/554,547

Applicant(s)

PAESEN

Examiner

E. SORBELLO

Art Unit

1633

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

#### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**RECEIVED**

FEB 26 2001

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

TECH CENTER 1600/2900



RECEIVED  
FEB 26 2001  
TECH CENTER 1600/2900

PATENT  
2488-1-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Guido Christiaan PAESEN *et al*  
SERIAL NO. : 09/554,547 EXAMINER : E. Sorbello  
FILED : July 7, 2000 ART UNIT : 1633  
FOR : TISSUE CEMENT

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on February 16, 2001.

David A. Jackson, Reg. No. 26,742  
(Name of Registered Representative)

*David A. Jackson 2/16/01*  
(Signature and Date)

STATEMENT IN SUPPORT OF THE FILING/SUBMISSION OF A  
NUCLEOTIDE/AMINO ACID SEQUENCE LISTING IN  
ACCORDANCE WITH 37 CFR §§1.821 - 1.825

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

Dear Sir:


DAVID A. JACKSON, attorney of record, hereby states as follows:

1. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
2. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g) herein does not include new matter.

RECEIVED  
FEB 22 2001  
TECH CENTER 1600/2900  
01 FEB 22 PM 5:01

3. I hereby declare that all statements made herein of the undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the U.S. Code, Section 1001 and that such willful false statements may jeopardize the validity of this Application or any patent issuing thereon.

DATED: February 16, 2001

  
\_\_\_\_\_  
DAVID A JACKSON  
Attorney for Applicants  
Registration No. 26,742